Physician profile
David E Winters
NPI 1013965987
$408.07
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $389 · 2020: $19.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $95.12 | 2019-2020 | |
| Pfizer INC. | $66.80 | 2019 | |
| Glaxosmithkline, LLC. | $49.12 | 2019 | |
| Sanofi-Aventis U.S. LLC | $45.03 | 2019 | |
| Amgen INC. | $40.81 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.64 | 2019 | |
| Boston Scientific Corporation | $17.57 | 2019 | |
| Abbott Laboratories | $17.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.92 | 2019 | |
| Cranial Technologies, INC | $12.33 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Winters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.